ClinicalTrials.gg
CompletedNCT02413580Updated Apr 24, 2020Results posted

A Study to Assess the Efficacy and Safety of IGIV-C in Patients With Myasthenia Gravis Exacerbations

A Phase 3 interventional study of IGIV-C in Myasthenia Gravis Exacerbations, sponsored by Grifols Therapeutics LLC. Completed at 31 sites in 12 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2020-04-24.

Sponsored by Grifols Therapeutics LLC (part of Grifols) · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
49
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 56 studies in Myasthenia Gravis with a site in France — 20 open to participants now, 32 under way, 16 of them phase 3. Myasthenia Gravis · France.

Enrollment
37th of 44
49 · median 123
Started
2015
with 2 others
Phase 3
27 of 56
5 open now
Registered
7th of 56
by date
Lead sponsor
3 of 56
Grifols Therapeutics LLC

Among the 56 studies in Myasthenia Gravis with a site in France, this one is the 37th largest by enrollment of the 44 interventional ones that give a count, is one of 3 that started in 2015, is one of 27 in phase 3, and was the 7th registered.

Myasthenia Gravis

330 studies on the registry are indexed under Myasthenia Gravis; 145 are open to participants now.

Browse Myasthenia Gravis studies →

Open to participants now

20 of the 56 studies in Myasthenia Gravis with a site in France are open now. Recruiting first, the newest first:

15 more — sign in →

All 20 open studies →

A study can be open while its sites in France have not opened yet or have stopped. Only those recruiting at a site in France →

Who these studies take

Of the 104 Myasthenia Gravis studies recruiting now, 64 (62%) set no upper age limit and 23 (22%) stop at 75 or younger; 16 take children under 18; 13 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 56 studies in Myasthenia Gravis with a site in France, or all of them as a file.
02

Study summary

This was a multicenter, prospective, open-label, non-controlled study to assess the efficacy and safety of an IV dose of 2 g/kg of IGIV-C in subjects with MG exacerbations.

Read the detailed description

The study consisted of a single dose course of IGIV-C treatment followed by 28-days of post-infusion assessments. The total duration of study participation for each subject was up to 28 ± 2 days. Approximately 50 subjects, ages 18 or greater, were planned to be enrolled in the study and receive a single, total dose of 2 g/kg of IGIV-C over 2 consecutive days (dose of 1 g/kg per day) across multiple centers in Argentina, Canada, Europe, and South Africa.

03

Conditions studied

  • Myasthenia Gravis Exacerbations

Browse trials for

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Was male or female aged ≥18 years.
  • Subjects must be willing and able to provide written (if applicable, a legally authorized representative may provide informed consent on behalf of the subject).
  • Subjects who met the clinical criteria for diagnosis of MG with an exacerbation defined as worsening of MG symptoms as defined by an Myasthenia Gravis Foundation of America (MGFA) classification IVb or V.
  • Subjects on long-term (8 weeks) treatment for MG.
  • Female subjects of must have a negative test for pregnancy (human chorionic gonadotropin [HCG]-based assay).
  • Subjects must be willing to comply with all aspects of the clinical trial protocol, including blood sampling and long-term storage of extra samples, for the entire duration of the study.

Exclusion criteria

Exclusion Criteria:

  • Subjects who had received immune globulin treatment given by IV, subcutaneous or intramuscular route within the last 30 days.
  • Subjects with documentation of a lack of clinical response to intravenous immunoglobulin (IVIg) therapy for MG.
  • Subjects documented positive for antibodies directed against Muscle specific kinase (MuSK).
  • Subjects with (CS) treatment initiated within the last 8 weeks or modified within the last 2 weeks.
  • Subjects with plasma exchange (PLEX) within the last 30 days.
  • Subjects with MG exacerbation attributable to change in medication or infection or evident infection as defined by, but not limited to, the presence of at least one of the following diagnostic features: 1) axillary temperature ≥38°C, 2) positive blood culture of infective microorganism, 3) white blood cell count >12×10\^9/L and differential white blood cell count of >10% band neutrophils (>1.2×10\^9/L), and 4) pulmonary infiltrate with consolidation on chest X-ray. Alternatively, other signs and symptoms may be considered for the diagnosis of evident infection according to the Investigator's judgement.
  • Subjects with inadequate venous access.
  • Subjects with a history of anaphylactic reactions or severe reactions to any blood-derived product.
  • Subjects with a history of intolerance to any component of the products.
  • Subjects with a documented diagnosis of thrombotic complications to polyclonal IVIG therapy in the past.
  • Subjects with a history of recent (within the last year) myocardial infarction, stroke or uncontrolled hypertension.
  • Subjects who suffered from uncontrolled congestive heart failure, embolism or documented (ECG) changes indicative of myocardial ischemia or atrial fibrillation.
  • Subjects with current known hyperviscosity or hypercoagulable state.
  • Subjects currently receiving anti-coagulation therapy.
  • Subjects with a history of chronic alcoholism or illicit drug abuse (addiction) in the 12 months preceding the Baseline Visit.
  • Subjects currently receiving, or having received within 3 months prior to the Baseline Visit, any investigational medicinal product or device.
  • Subjects with a known Immunoglobulin A (IgA) deficiency and anti-IgA serum antibodies.
  • Subjects with renal impairment (i.e., serum creatinine exceeds more than 1.5 times the [ULN] for the expected normal range for the testing laboratory).
  • Subjects with (AST) or alanine aminotransferase (ALT) levels exceeding more than 2.5 times the ULN for the expected normal range for the testing laboratory.
  • Subjects with levels \<9 g/dL.
Terms in these criteria, in plain language(8)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
49 participants (actual)

Study arms

  • Experimental
    IGIV-C Treatment

    In this arm, subjects with myasthenia gravis exacerbations were treated with an IV dose of 2 g/kg of IGIV-C, which was administered over 2 consecutive days at a dose of 1 g/kg per day.

    Biological: IGIV-C

Interventions

  • BiologicalIGIV-C

    An IV dose of 2 g/kg of IGIV-C was administered over 2 consecutive days at a dose of 1 g/kg per day.

06

What researchers measure

Primary outcomes

  1. Change in Quantitative Myasthenia Gravis (QMG) Scale Score

    Mean Change in Quantitative Myasthenia Gravis (QMG) Scale Score from Baseline (Day 0) to Day 14. The minimum and maximum scores of the QMG Scale are 0 and 39, respectively, and a higher score means a worse outcome.

    Time frame: From Baseline (Day 0) to Day 14

Secondary outcomes

  1. Percentage of Subjects With Clinical Improvement Assessed by QMG

    The percentage of subjects with clinical improvement at Day 14 as assessed by the Quantitative Myasthenia Gravis (QMG) scale in the Evaluable population is presented, in which clinical improvement is defined as at least 3-point decrease in QMG score from Baseline (Day 0) to Day 14. The minimum and maximum scores of the QMG scale are 0 and 39, respectively, and a higher score means a worse outcome.

    Time frame: Baseline (Day 0) to Day 14

  2. Percentage of Subjects With Clinical Improvement Assessed by MG-Activities of Daily Living (MG-ADL) Scale

    The percentage of subjects with clinical improvement at Day 14 as assessed by the MG-ADL Scale in the Evaluable population is presented, in which clinical improvement is defined as at least 2-point decrease in the MG-ADL score. The minimum and maximum scores of the MG-DAL scale are 0 and 24, respectively, and a higher score means a worse outcome.

    Time frame: Baseline (Day 0) to Day 14

  3. Percentage of Subjects With Clinical Improvement Assessed by the MG Composite

    The percentage of subjects with clinical improvement at Day 14 as assessed by the MG Composite scale in the Evaluable population is presented in which clinical improvement is defined as at least 3-point decrease in the MG Composite score. The minimum and maximum scores of the MG Composite scale are 0 and 50, respectively, with a higher score meaning a worse outcome.

    Time frame: Baseline (Day 0) to Day 14

07

Results

Posted Apr 24, 2020

Participant flow

Participant flow — Overall Study
MilestoneIGIV-C Treatment
Started49
Completed46
Not completed3

Outcome measures

PrimaryChange in Quantitative Myasthenia Gravis (QMG) Scale Score

Mean Change in Quantitative Myasthenia Gravis (QMG) Scale Score from Baseline (Day 0) to Day 14. The minimum and maximum scores of the QMG Scale are 0 and 39, respectively, and a higher score means a worse outcome.

Time frame:
From Baseline (Day 0) to Day 14
Reported as:
Mean · score on a scale
Change in Quantitative Myasthenia Gravis (QMG) Scale Score
score on a scaleIGIV-C Treatment
Change in Quantitative Myasthenia Gravis (QMG) Scale Score-6.4 ± 5.15
Statistical analysis
  • IGIV-C Treatment · Paired t-test · p = <0.001 · Mean difference (final values): -6.4 · 95% CI -7.957 to -4.787
SecondaryPercentage of Subjects With Clinical Improvement Assessed by QMG

The percentage of subjects with clinical improvement at Day 14 as assessed by the Quantitative Myasthenia Gravis (QMG) scale in the Evaluable population is presented, in which clinical improvement is defined as at least 3-point decrease in QMG score from Baseline (Day 0) to Day 14. The minimum and maximum scores of the QMG scale are 0 and 39, respectively, and a higher score means a worse outcome.

Time frame:
Baseline (Day 0) to Day 14
Reported as:
Count of participants · Participants
Percentage of Subjects With Clinical Improvement Assessed by QMG
ParticipantsIGIV-C Treatment
Percentage of Subjects With Clinical Improvement Assessed by QMG33
SecondaryPercentage of Subjects With Clinical Improvement Assessed by MG-Activities of Daily Living (MG-ADL) Scale

The percentage of subjects with clinical improvement at Day 14 as assessed by the MG-ADL Scale in the Evaluable population is presented, in which clinical improvement is defined as at least 2-point decrease in the MG-ADL score. The minimum and maximum scores of the MG-DAL scale are 0 and 24, respectively, and a higher score means a worse outcome.

Time frame:
Baseline (Day 0) to Day 14
Reported as:
Count of participants · Participants
Percentage of Subjects With Clinical Improvement Assessed by MG-Activities of Daily Living (MG-ADL) Scale
ParticipantsIGIV-C Treatment
Percentage of Subjects With Clinical Improvement Assessed by MG-Activities of Daily Living (MG-ADL) Scale38
SecondaryPercentage of Subjects With Clinical Improvement Assessed by the MG Composite

The percentage of subjects with clinical improvement at Day 14 as assessed by the MG Composite scale in the Evaluable population is presented in which clinical improvement is defined as at least 3-point decrease in the MG Composite score. The minimum and maximum scores of the MG Composite scale are 0 and 50, respectively, with a higher score meaning a worse outcome.

Time frame:
Baseline (Day 0) to Day 14
Reported as:
Count of participants · Participants
Percentage of Subjects With Clinical Improvement Assessed by the MG Composite
ParticipantsIGIV-C Treatment
Percentage of Subjects With Clinical Improvement Assessed by the MG Composite37

Adverse events

Collected over Subjects with MG exacerbations not attributable to an infection or change in medication were planned to receive 2 g/kg of IGIV-C on Day 0 (Baseline) and on Day 1 (dosed as 1 g/kg per day), followed by 28 days of post-infusion assessments. During this 30-day period, the adverse event data were collected.. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
IGIV-C Treatment0/49 (0%)0/49 (0%)30/49 (61.2%)
Most frequent other events
Most frequent other events
EventIGIV-C Treatment
HeadacheNervous system disorders19/49
PyrexiaGeneral disorders8/49
UrticariaSkin and subcutaneous tissue disorders4/49
Influenza like illnessGeneral disorders3/49
VomitingGastrointestinal disorders3/49
RashSkin and subcutaneous tissue disorders3/49

Baseline characteristics

The demographic data are from the Safety population that consisted of all 49 subjects who were infused with any amount of study drug.

Age, Categorical
Age, Categorical(Participants)IGIV-C Treatment
<=18 years2
Between 18 and 65 years40
>=65 years7
Age, Continuous
Age, Continuous(year)IGIV-C Treatment
Mean47.3 ± 15.22
Sex: Female, Male
Sex: Female, Male(Participants)IGIV-C Treatment
Female34
Male15
Race (NIH/OMB)
Race (NIH/OMB)(Participants)IGIV-C Treatment
American Indian or Alaska Native1
Asian1
Native Hawaiian or Other Pacific Islander0
Black or African American2
White44
More than one race0
Unknown or Not Reported1
Region of Enrollment
Region of Enrollment(participants)IGIV-C Treatment
Canada3
Argentina3
Latvia10
Romania5
Belgium6
Czechia4
Poland4
South Africa2
France2
Russia10
08

Study locations

31 sites
  • Hospital Italiano
    Buenos Aires, C1181ACH, Argentina
  • Hospital General de Agudos Dr. J. M.
    Buenos Aires, C1221ADC, Argentina
  • Hospital Cordoba
    Cordoba, X5004CDT, Argentina
  • AZ St Lucas Gent
    Ghent, East Flanders 9000, Belgium
  • UZ Leuven
    Leuven, 3000, Belgium
  • University of Alberta Hospital
    Edmonton, Alberta T6G 2B7, Canada
  • London Health Sciences Centre
    London, Ontario N6A 5A5, Canada
  • University Health Network (UHN) - Toronto General Hospital
    Toronto, Ontario M5G 2C4, Canada
  • Fakultni nemocnice Brno, Neurologicka klinika
    Brno, Czechia
  • Fakultni nemocnice Ostrava, Neurologická klinika
    Ostrava, 70800, Czechia
  • Vseobecna fakultni nemocnice v Praze
    Prague, 12808, Czechia
  • East Tallinn Central Hospital
    Tallinn, 10138, Estonia
  • Hopital Neurologique Pierre Wertheimer
    Bron, Lyon 69677, France
  • Hôpital Albert Michallon
    Grenoble, 38700, France
  • Hopital Roger Salengro
    Lille, 59037, France
  • Hôpital de la Timone
    Marseille, 13385, France
  • Hôpital Hautepierre Strasbourg
    Strasbourg, 67200, France
  • CHU de Toulouse - Hôpital Purpan
    Toulouse, 31059, France
  • Jahn Ferenc Del-Pesti Korhaz
    Budapest, 1204, Hungary
  • Pest Megyei Flor Ferenc Korhaz
    Kistarcsa, 2143, Hungary
  • Szabolcs-Szatmár-Bereg Megyei Kórházak és Egyetemi Oktatókórház
    Nyíregyháza, Hungary
  • University of Szeged, Faculty of Medicine
    Szeged, 4400, Hungary
  • Zala Megyei Korhaz
    Zalaegerszeg, 8900, Hungary
  • Riga East Clinical University Hospital
    Riga, LV-1038, Latvia
  • Uniwersyteckie Centrum Kliniczne
    Gdansk, Poland
  • Institutul Clinic Fundeni
    Bucuresti, 22328, Romania
  • Spitalul Clinic Judetean de Urgenta Targu-Mures
    Targu Mures, RO540136, Romania
  • State Budgetary Institution of Healthcare of Nizhniy Novgorod region. Nizhniy Novgorod Regional Clinical Hospital named after N.A.Semashko
    Nizhniy Novgorod, 603126, Russian Federation
  • Saint-Petersburg State Budgetary Institution of Healthcare. City Multi-field Hospital # 2
    Saint Petersburg, 357538, Russian Federation
  • State Budgetary Institution of Healthcare "Samara Regional Clinical Hospital. V.D.Seredavin
    Samara, 443095, Russian Federation
  • Groote Schuur Hospital,
    Cape Town, South Africa
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

10

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Mar 2015, a primary completion of Apr 2018 and a completion of Apr 2018. It does not say whether these dates are actual or estimated.

Results were first posted in Apr 2020, 2 years after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 7, 2015
First posted
Apr 10, 2015
Start
Mar 2015
Primary completionActual
Apr 2018
CompletionActual
Apr 2018
Results first posted
Apr 24, 2020
Last update
Apr 24, 2020
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 24, 2020, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT02413580
Responsible party
Sponsor
First posted
Apr 10, 2015
Start date
Mar 2015
Primary completion
Apr 2018
Completion
Apr 2018
Results posted
Apr 24, 2020
Last update
Apr 24, 2020

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Apr 2020. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Immunoglobulins, Intravenous

Start the discussion